Adamas Pharmaceuticals has announced that its Phase III EASE LID clinical trial evaluating ADS 5102 (amantadine HCl) extended-release capsules for...
Adamas Pharmaceuticals has announced positive findings from its lead Phase III study (EASE LID) evaluating ADS 5102 (amantadine HCl) extended-release...
Adamas Pharmaceuticals, Inc. announced that the FDA has approved Gocovri (amantadine) extended release capsules (previously ADS-5102) for treatment of dyskinesia...